Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 17/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 17/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 17/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 17/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 17/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 17/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820267 | 1.00 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2825928 | 0.85 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4674488 | 0.85 | PSEN1 (0.49) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2245584 | 0.82 | KMT2A (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2976475 | 0.80 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1793314 | 0.80 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1508716 | 0.79 | TLR2 (0.53) | — | |
| SCHEMBL1508827 | 0.79 | TLR2 (0.53) | — | |
| SCHEMBL27836700 | 0.79 | TLR2 (0.53) | — | |
| SCHEMBL2818839 | 0.78 | PSEN1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1958939-A2 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | Pfizer Products Inc. (US) | 2008-08-20 | — | — | EP | claimed |
| EP-1735285-B1 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-07-23 | — | — | EP | claimed |
| US-20070265327-A1 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-15 | — | — | US | claimed |
| US-7244757-B2 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-17 | — | — | US | claimed |
| EP-1735285-A2 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2005095348-A2 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20050222239-A1 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | claimed |
| US-7468386-B2 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1958939-A2 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | Pfizer Products Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1735285-B1 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PROD INC (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070265327-A1 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-15 | — | — | US | disclosed |
| US-7244757-B2 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1735285-A2 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005095348-A2 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222239-A1 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222239-A1 | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | APP, PRNP, BACE1 | PSEN1 4/4885PSEN2 7/4885APH1B 21/4885 |
| US-20070265327-A1 | PYRAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, PRNP, BACE1 | PSEN1 4/4885PSEN2 7/4885APH1B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.